A Novel Mutation of Thyroid Hormone Receptor Beta (I431V) Impairs Corepressor Release, and Induces Thyroid Hormone Resistance Syndrome

ABSTRACT

Resistance to thyroid hormone (RTH) is a rare disorder characterized by variable tissue hyporesponsiveness to thyroid hormone, usually caused by mutations in the thyroid hormone receptor beta (TRβ). We describe a large Brazilian family harboring a novel mutation affecting TRβ gene and inducing RTH. A 14-year-old girl was found to have elevated free T₄ and free T₃ plasma concentrations in coexistence with unsuppressed TSH and a questionable goiter. The diagnosis of RTH was verified by identification of a novel mutation (I431V) in the TRβ gene. Sixteen asymptomatic relatives of the proposita are also affected by the mutation. Functional studies showed that I431V mutation exerts dominant-negative effect on wild type TRβ, mainly by impairment of ligand-dependent release of corepressor SMRT. The presence of this mutation reduces potency, but does not affect efficacy of thyroid hormone action, in accordance with the clinical picture of eumetabolism of the affected individuals.

Keywords: Thyroid hormone resistance; Thyroid hormone receptor; Coregulator; Mutation

INTRODUCTION

Thyroid hormone resistance (RTH) is a rare autosomal dominant disorder, characterized by reduced target tissues responsiveness to thyroid hor-
Thyroid Hormone Resistance Syndrome

Azevedo et al.

Free thyroxine (FT4) in serum, and elevated or inappropriate elevated levels of thyroid-stimulating hormone (TSH). Clinical phenotype is heterogeneous, varying between different families and also among affected members of the same family. Characteristically, there is a paucity of specific clinical manifestations. When present, the most common clinical findings are goiter, learning disabilities with or without hyperactive behavior, developmental delay, and sinus tachycardia. Symptoms of hypothyroidism may coexist in the same patient, suggesting variable degrees of resistance in different tissues (4,5).

Thyroid hormone receptors (TRs) are ligand-dependent transcription factors, which mediate the biological activities of T3. TRs exist in two isoforms that are encoded for by the THRA and THRB genes, which are located on chromosomes 3 and 17, respectively. The distribution of TRα and TRβ in the diverse organs is heterogeneous, although thyroid hormone has the same affinity for both isoforms (6).

TRs modulate gene expression by binding specific DNA sequences, known as thyroid response elements (TREs), found in the promoters of TR-regulated genes. TREs are composed of repeats of the consensus half-site AGGTCA in a variety of different orientations, including direct repeats spaced by four nucleotides (DR4), inverted palindromes (F2) and palindromes (TREpal) (7). TR activities are primarily controlled by the presence of ligand. Unliganded TRs recruit corepressor proteins such as N-CoR and SMRT, which, in turn, form part of a large corepressor complex that represses transcription of nearby genes (8,9). Hormone binding induces conformation changes in TR that cause corepressor release and subsequent recruitment of co-activators such as GRIP1 and SRC-1 and the TRAP/DRIP complex (8,9). TR activities are, however, also influenced by choice of oligomeric state. TRs preferentially form heterodimers with retinoid X receptors (RXRs), but also function as homodimers or monomers (7,8).

The molecular basis of RTH in approximately 85% of subjects is heterozygous mutations of the thyroid hormone receptor (TR) β gene, resulting in impaired triiodothyronine (T3) binding and/or transactivation function. The severity of resistance depends on the degree of impaired ligand binding and/or interaction with tissue-specific nuclear cofactors (10,11). Characterization of families and sporadic cases with RTH has shown that all the mutations are located in the ligand binding domain of TRβ1 and thus far, no mutations have been identified in the DBD or N-terminal region of TRβ1 (9). Moreover, no germline mutations in TRα1 have been described in humans (6). Interestingly, in addition to being non-functional, the RTH mutants inhibit the action of their wild type counterparts. This dominant-negative effect by the mutant receptors may explain the dominant mode of inheritance as well as resistance to hormone action (8-9).

In this study, we describe the clinical findings and laboratory data from three generations of a large family harboring a novel TRβ mutation (I431V), and evaluate the functional profile of this mutant TRβ through in vitro and cell culture studies. Our data suggest that the mutant I431V TRβ impairs corepressor release, leading to a clinical picture of RTH.

SUBJECTS AND METHODS

Case Report

The proposita, a 14-year-old Brazilian girl, came to medical attention due to goiter. She had no other complaints and had normal neurological and psychological development. On physical examination, she had normal stature, normal heart rate, and no neurological or other abnormalities. Serum TSH was 1,92 μIU/L (normal range, 0,3–5,0), free T4 (FT4) was 2,31 ng/dL (normal range, 0,75–1,8), and free T3 (FT3) was 0,78 ng/dL (normal range, 0,3–0,51), on repeated occasions. Thyroid peroxidase antibody was negative, and thyroid ultrasonography was normal. Blood samples were obtained from all family members, all of them asymptomatic for thyroid diseases. Informed consents were obtained for this study approved by the Ethics Committee from the University of Brasilia.

Measurements of hormones in serum

FT4, FT3, and TSH were measured by chemiluminescence assay, using Kit ADVIA CENTAUR (Centaur, Siemens).

TRβ sequencing

Genomic DNA of the proposita and her family members was extracted from 50μl whole blood by the Chel-
ex-100 method (12), and exons 9 and 10 of the TRβ were gene amplified through PCR, using the sense and antisense oligonucleotide primers described by Adams and cols. (13). The products of amplification were sequenced directly using the automated sequencing ABI-377 (Perkin-Elmer Corp., Foster City, CA, USA).

To examine the family members we used PCR based restriction fragment length polymorphism (RFLP) analysis since the sequence variant identified here introduces a new BccI (Fermentas Inc., Hanover, MD, USA) recognition site in exon 10.

Plasmids
To perform functional studies, we used the following plasmids: T3-inducible reporters containing two copies of each TRE driving luciferase expression, mammalian (pCMX) expression vectors for TR and RXR (14), GST fusion expression vectors (pGEX) for SMRT (15), SRC-1 (16) and RXR (14).

New TR mutants reported in our studies (pCMX-TRβI431V and pGEX-TRI431V) were created in existing vectors using QuikChange site-directed mutagenesis kits (Stratagene). The construct was checked for correct DNA insertion and presence of mutation by automated DNA sequencing ABI-377 (Perkin-Elmer Corp., Foster City, CA, USA).

Mammalian Cell Culture, Electroporation, and Luciferase Assays
Human promonocyte U937 cells were maintained at 37°C, 5% CO₂, subcultured in RPMI 1640 media with 10% newborn bovine serum, 2mM glutamine, 50units/ml penicillin, and 50g/ml streptomycin. Transfections were carried out as described previously (17). After incubation for 24h at 37°C with ethanol or T3, cells were collected by centrifugation, and pellets were solubilized by addition of 150μl of 0.25M Tris-HCl, pH 7.6, containing 0.1% Triton X-100. Luciferase activity was analyzed by standard methods (luciferase assay system, Promega). Experiments were performed in triplicate and expressed as fold induction ± SEM.

Glutathione S-Transferase Pull-Down Assays
pCMX-TRβ1wt or pCMX-TRI431V vectors were used to produce radiolabeled full-length receptor in vitro, using the TNT-Coupled Reticulocyte Lysate System (Promega) and [³⁵S]methionine. GST SRC1a (381–882), GST-RXR (full-length), and GST-SMRT (987–1491) fusion proteins were prepared using conventional protocols (Pfizer, New York, NY). In brief, the plasmids were transformed into BL21, cultured into 2xLB medium, pelleted and resuspended in 1xTST buffer (50mM Tris pH 7.5, 150mM NaCl, and 0.05% Tween 20) with 1mM DTT, 0.5mM phenylmethylsulfonyl fluoride, and protease inhibitor cocktail 1:1000 (Sigma, St. Louis, MO). Then, the solution was incubated with lysozyme and sonicated (three 2.5-min cycles, amplitude 70%, 1 pulse/s with a break of 5 min between each cycle). The debris were pelleted and the supernatant was incubated for 2h with 500μl of glutathione-Sepharose 4B beads equilibrated with 1x TST. GST fusion protein beads were washed with 1x TST containing 0.05% Nonidet P-40 and resuspended in 1x TST with 1mM DTT, 0.5mM phenylmethylsulfonyl fluoride, protease inhibitor cocktail 1:1000 (Sigma), and 50% glycerol, and then stored at minus 20°C. All procedures above were carried out at 4°C. For the binding assay, the glutathione bead suspension containing 4 μg of GST fusion protein was incubated with 3μl of 35S-labeled protein in 150μl of 1x TST buffer with 0.1% Nonidet P-40, 0.1% Triton X-100, 1 mM DTT, and 2 g/ml bovine serum albumin, in the presence of 10⁻⁶M T3 or vehicle. After a 2h incubation at 4°C, the beads were washed with the same incubation buffer. The beads with associated proteins were analyzed on 10% SDS-polyacrylamide gels and visualized by autoradiography.

T3 Binding Assay
TRs were expressed using the TNT T7 quick coupled transcription translation system (Promega). The affinities of T3 binding were determined using a saturation binding assay. 15 fmol of each in vitro translated protein were incubated overnight at 4 °C with varying concentrations of [¹²⁵I]T3 (PerkinElmer Life Sciences) in 100μl of E400 buffer (400mM NaCl, 20mM KPO₄, pH 8, 0.5mM EDTA, 1.0mM MgCl₂, 10% glycerol), 1mM monothioglycerol, and 50μg of calf thymus histones (Calbiochem). The bound [¹²⁵I]T3 was isolated by gravity flow through a 2ml Sephadex G-25 (Amersham Biosciences) column and quantified using a gamma-counter (Cobra II – PACKARD, Austrália). Binding curves were fit by nonlinear regression, and equilibrium dissociation constant (Kd) values were calculated using the one-site saturation binding model, contained in the Prism version 4.00 program (GraphPad Software, Inc., San Diego, CA).
Statistics
Student’s t-test or one-way analysis of variance followed by Student-Newman-Keuls multiple comparison test was employed for assessment of significance (Prism version 4.0; GraphPad Software Inc., San Diego, CA). Differences were considered to be significant at p<0.05.

RESULTS
A novel mutation was found in the TRβ of the proposita and her family
Sequencing of PCR products in both directions revealed an heterozygous missense mutation (A → G) in exon 10 of the TRβ gene, which resulted in replacement of a normal isoleucine for a valine at codon 431 (I431V).

Investigation of family members, by PCR based restriction fragment length polymorphism (RFLP) analysis, showed other 16 heterozygous individuals (Figure 1). Affected members are distributed through three generations, and none of them presented any thyroid related symptom or have had previously suspected RHT diagnosis.

Once the proposita showed only minimal phenotype alterations, characterized by normal physical examination, including absence of goiter and tachycardia, and mild elevation on FT3 and FT4 levels with unsuppressed TSH levels, we decided to investigate all of the affected family members. Among these 16 individuals, all but three had serum thyroid hormone levels similar to those found in the proposita (Figure 2). One affected patient’s aunt had elevated TSH level (51mUI/L) with low-normal FT3, reduced FT4 and a positive test for thyroperoxidase autoantibodies, configuring concomitant primary hypothyroidism, not previously suspected (data not shown). Other two affected members presented normal hormonal dosages (Figure 2). Moreover, all of them were completely asymptomatic, including the hypothyroid patient.

I431V reduces sensitivity, but does not affect efficacy of thyroid hormone action
The transcriptional properties of the I431V mutant were examined by transfection assays, using either the mutant or wild type TRβ1 isoform together with a reporter gene containing positively regulated thyroid hormone receptor response elements (TREs), in eukaryotes U937 cells. At lower T3 concentrations, transient transfection studies with a reporter gene containing DR4, F2 and TREpal responsive element showed decreased transcriptional activation induced by TRβ I431V. Otherwise, utilizing higher amounts of T3, this defect has been overcome. Therefore, at 100 nM and 1 μM T3 concentrations, TRβ I431V transcriptional activity was fully, and achieved the greater maximal response comparable to wt TRβ1 (Figure 3A, B and C). EC50 values obtained at DR4 responsive element were 33 fold greater for TRβ I431V, compared to wt TRβ (EC50 for wt TRβ 9.91 x 10^-9 M; EC50 for TRβ I431V...
**Figure 2.** Hormone values in a family with thyroid hormone resistance syndrome (RHT). N = unaffected first grade family members to persons with RHT. Dotted lines show normal ranges.

**Figure 3.** Transcriptional effects of increasing doses of T3 at DR4, F2, TREpal and TSH responsive elements. U937 cells were cotransfected with I431V TRβ (▲) or wt TRβ (■), and with firefly luciferase reporter gene driven by a promoter containing the various responsive elements sequence. The activation value for each T3 concentration is the mean of triplicate determinations.
Similar results were observed at F2 responsive element, where EC50 for TRβ I431V was 5 fold greater than for wt TRβ (EC50 for wt TRβ 1.63 x 10^-8 M vs 8.17 x 10^-8 M for I431V TRβ), and at TREPα, where it was 3 fold greater for TRβ I431V (EC50 1.06 x 10^-3 for wt TRβ vs 3.26 x 10^-3 for I431V TRβ).

We examined next the mutant transcriptional properties with the negatively regulated target gene promoter, i.e. the human pituitary TSHα subunit. At TSH promoter, TRβ I431V showed a reduced capacity to repress transcription at lower T3 concentrations (1nM and 10nM), but not at higher concentrations of 100 nM and 1μM. Therefore, the dose-response curve is also slightly shifted to the left, as shown in Figure 3D. Collectively, these results showed that I431V TRβ has impaired sensitivity, keeping the maximum response (efficacy) similar to wt TRβ1.

**I431V exerts dominant-negative effect on TRβ**

Having established the functional capabilities of I431V TRβ, the ability of this mutant to modulate the activity of wt TRβ1 (dominant negative effect) was examined. Wild type β receptor was co-transfected with equal concentrations of I431V. Under these conditions, I431V markedly inhibited both positive (DR4) and negative (TSH) transcriptional responses mediated by the wild type receptor (Figure 4).

*Figure 4. Dominant negative effect of I431V TRβ. U937 cells were treated with 100nmol/liter of T3. A: fold activation at DR4 responsive element. B: % of repression at TSH responsive element.*
I431V demonstrate impaired ligand-dependent release of SMRT

To further characterize whether the I431V mutant retained the ability to interact with nuclear co-factors, we performed GST pull down assay. Figure 5A shows that TRβ I431V recruitment of the coactivator SRC-1 is slightly reduced, compared to TRβ wt. However, it is noteworthy that I431V TRβ retains the corepressor SMRT stronger than does wt TRβ, even at higher T3 concentrations, such as 100 nM and 1 μM (Figure 5B). On the contrary, I431V TRβ heterodimerization with RXR was similar to wt TRβ (Figure 6).

I431V binding affinity is reduced

T3 binding assay was performed to address thyroid hormone binding affinity of TRβ I431V. Our results showed that TRβ I431V affinity for T3 was 2.6 times lower than TRβ wt (Kd for TRβ wt 0.188nM vs 0.49nM for I431V).

DISCUSSION

RHT is an inherited condition induced by defects that reduce the responsiveness of the target tissues to thyroid hormone (1). The precise incidence is unknown, but it is estimated to be 1 case per 40,000 live births (18). In the untreated patient, elevation of serum free T4 is a sine qua non requirement for the diagnosis of the syndrome (3,4).

Likewise, RHT diagnosis must be suspected in every patient that presents persistent elevation of circulating free T4 and free T3, in association with nonsuppressed serum TSH, and in the absence of intercurrent illness, drugs, or alteration of thyroid hormone transport serum proteins. Differential diagnosis must concern autonomous hypersecretion of TSH associated with pituitary adenomas. The tumors may be demonstrated by magnetic resonance imaging of the pituitary gland, or this diagnosis may be made by elevation of circulating α-subunit, or by failure of serum TSH to increase above the basal level in response to TRH (3).

Here, we describe an asymptomatic female patient that presented characteristic thyroid hormone levels alterations that narrowed the possibility of RHT. TSH hypersecretion was discharged by pituitary imaging that was normal.

The THRB gene consists of 10 exons (19); the aforementioned mutations are located in the last 4 exons, which code for the hinge region and, more frequently, the ligand-binding domain of the receptor, at the carboxyl-terminus of the TRβ. The majority of these mutations result in a reduction in T3-binding and/or an impairment in transactivation (20). There have been described at least 122 mutations affecting THRB gene, including deletions, insertions, and much more frequently, point mutations (21-23). The largest family reported in the literature until now is composed by 36 persons harboring a missense mutation at THRB gene (24).

The mutation identified in this family results in an alteration in codon 431 in helix 11 (H11) of the ligand-binding domain of TRβ, a residue oriented towards the interior of receptor’s structure. Mutations affecting this region, at codon 429, normally presents itself as a predominantly pituitary pattern of RHT in humans (10,25,26). Another mutation, also localized at codon 431 but resulting in a different amino acid substitution, I431T, has been previously described as causing predominantly pituitary RHT, concerning clinical presentation and TSH, T3 and T4 levels in serum obtained from the affected patient (9). Afterwards, in another study using reporter gene assays with positive and negative response elements, Safer et al. demonstrated that I431T mutation causes generalized resistance to thyroid hormone (27).

In our study, I431V TRβ also showed a dominant negative effect upon positive (DR4) and negative (TSH promoter) regulated genes, behaving biochemically as a generalized resistance to thyroid hormone. In spite of the fact that I431T TRβ mutant showed a moderate reduction of T3 binding affinity, I431V mutant displayed a slightly impairment in affinity. This difference can be explained by the fact that both valine and isoleucine have a
hydrophobic side group. Consonant with these findings, at higher T₃ concentrations, the mutant I431V TRβ restored coactivator (SRC-1) recruitment, and retained the ability to regulate transcription.

Interestingly, in I431V mutant, T₃ ligand-dependent corepressor release was markedly lower than expected from the impaired ligand-binding affinity. Even at higher T₃ doses, with normal recruitment of SRC-1, I431V still binds to SMRT. Similar results were described in other RTH mutants. Mutations at the receptor carboxyl terminus in the ligand-inducible trans-activation function (AF-2) region, such as L454S, shows similar pattern. This mutant interacts stronger with a nuclear receptor corepressor (NCoR) than does the wild-type receptor, and the T₃-dependent release of NCoR is markedly impaired (28).

Other studies have shown that a number of RTH mutants interact aberrantly with corepressors. For two mutations (P453A and P453H), involving a proline residue that precedes an amphipathic helix at the receptor carboxy terminus, ligand-dependent corepressor release was markedly reduced. Furthermore, when introduced into a RTH mutant, artificial mutations that abolished corepressor interaction abrogated the dominant negative activity of RTH mutants (29). Another mutation, R383H, localized in the loop between H9 and H10, induces resistance to thyroid hormone and impairs corepressor release (25,30). These properties are shared by another mutant (R429Q), which is located in H11 (25). Notwithstanding, R429Q is associated with greater impairment of negative than positive transcriptional function. This finding differs from the I431V, since this RTH mutant impairs both positive and negative responsive genes (25).

We also showed a reduced affinity of the I431V mutant receptor for thyroid hormone. Altogether, these findings are consistent with the clinical picture of euthyroidism of the affected individuals.

Up to now, no specific treatment is available to correct the defect on RTH and patients in euthyroidism should not be treated. However, follow-up of patients with RTH has fully been recommended, once the clinical presentation may vary among individuals with the same mutation or even in the same individual throughout lifetime (20,31).

In this study, we have described a large family harboring a novel mutation of TRβ gene that impairs corepressor release, and induces thyroid hormone resistance syndrome. Although the majority of the heterozygous patients presented only minimal alterations in thyroid hormone levels, two of the affected individuals showed normal hormonal dosages, which illustrate the variability of clinical presentation that occurs in RTH, even among members of the same family. Knowledge about this illness is clinically relevant, at least for family counseling, and is also very important to contribute to a better comprehension of thyroid physiology.

Acknowledgments: This work was supported by Brazilian Research Council CNPq 486388/2006-9 and Finatec (02/2006 – Universidade de Brasilia). Disclosures: All the authors report no conflicts of interest.

REFERENCES

13. Adams M, Matthews C, Collingswood T, Tone Y, Beck-Peccoz P, Chatterjee KK. Genetic analysis of 29 kindreds with generali-
Thyroid Hormone Resistance Syndrome
Azevedo et al.

1312


29. Yoh SM, Chatterjee VK, Pravalsky ML. Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors. Mol Endocrinol 1997;11(4):470-80.


Correspondence to:
Francisco de Assis Rocha Neves
Laboratório de Farmacologia Molecular, UnB
Caixa Postal 4473
70919-970 Brasilia, DF
E-mail: chico@unb.br